ProShare Advisors’s Protalix BioTherapeutics PLX Stock Holding History

ProShare Advisors’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,589	Closed	-$23K	–	1995
2026 Q1	$23K	Sell	10,589 -2,548	-19%	-$6.32K	﹤0.01%	1834
2025 Q4	$23.6K	Buy	13,137 +1,215	+10%	+$2.48K	﹤0.01%	2013
2025 Q3	$26.5K	Sell	11,922 -2,375	-17%	-$3.87K	﹤0.01%	1977
2025 Q2	$21.2K	Buy	+14,297	New	+$29.2K	﹤0.01%	2066
2024 Q2	–	Sell	-12,147	Closed	-$15.3K	–	1963
2024 Q1	$15.3K	Buy	12,147 +1,168	+11%	+$1.74K	﹤0.01%	1981
2023 Q4	$19.5K	Buy	+10,979	New	+$17.1K	﹤0.01%	1920

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ProShare Advisors's PLX Position: Q2 2026 in Review

ProShare Advisors sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 10,589 shares — an estimated $23K sold.

ProShare Advisors first reported a position in PLX in Q4 2023 and held it in 6 quarters. The position peaked at $26.5K in Q3 2025. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

ProShare Advisors reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
ProShare Advisors sold 10,589 Protalix BioTherapeutics shares in Q2 2026, an estimated $23K.
ProShare Advisors first reported a position in Protalix BioTherapeutics in Q4 2023 and held it in 6 quarters.
ProShare Advisors's Protalix BioTherapeutics position peaked at $26.5K in Q3 2025.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.